trending Market Intelligence /marketintelligence/en/news-insights/trending/pwot0hy3kbototehzte3wa2 content esgSubNav
In This List

Spring Bank Pharmaceuticals prices common stock offering

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Spring Bank Pharmaceuticals prices common stock offering

Spring Bank Pharmaceuticals Inc. priced an underwritten public offering of 3 million common shares at $12.50 each.

The Hopkinton, Mass.-based biopharmaceutical company expects to raise gross proceeds of $37.5 million.

Underwriters have a 30-day option to buy up to 450,000 additional common shares at the offering price.

Spring Bank expects the offering, which is subject to customary closing conditions, to close on or about Aug. 13.

Net proceeds will be used on clinical trials, nonclinical studies, research and development as well as general corporate purposes.

Jefferies and Piper Jaffray are acting as joint book-running managers for the offering.